US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.
CTP-656 can be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Vertex Pharmaceuticals executive vice-president and chief medical officer Dr Jeffrey Chodakewitz said: "Our vision is to develop the most effective and convenient medicines for people with CF.
"We look forward to exploring once-daily regimens that combine CTP-656 with other potential medicines from our broad CF pipeline that treat the underlying cause of the disease."
As part of the agreement, Vertex will pay $160m to Concert for all development and commercialisation rights to CTP-656 globally.
If it is approved as part of a combination regimen to treat CF, Concert may receive up to another $90m based on regulatory approval in the US and reimbursement in the UK, Germany or France.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataConcert developed CTP-656 by applying deuterium chemistry to modify Vertex's CFTR potentiator, ivacaftor, which is approved in the US, Europe, Canada and Australia for people with CF.
At present, Concert is conducting a Phase II study of CTP-656 in people with CF who have gating mutations.
CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene.
The rare, life-threatening genetic disease CF affects about 75,000 people in North America, Europe and Australia.
